Analyst Puneet Souda from Leerink Partners maintained a Buy rating on Natera (NTRA – Research Report) and increased the price target to $220.00 from $200.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Puneet Souda has given his Buy rating due to a combination of factors that highlight Natera’s strong market position and growth potential. Natera’s leadership in the minimal residual disease (MRD) market, which is significantly underpenetrated, positions it well for continued expansion. The company’s flagship product, Signatera, has shown impressive growth, surpassing management’s expectations for clinical test volumes and capturing over 90% market share in its segment.
Additionally, Natera’s recent financial performance has been robust, with oncology segment revenues significantly exceeding expectations. The company has raised its revenue growth guidance, reflecting confidence in its future prospects. Key upcoming catalysts, such as new product launches, potential guideline inclusions, and trial readouts, further support the positive outlook. These factors, combined with Natera’s history of exceeding expectations, underpin Souda’s decision to maintain an Outperform rating and raise the price target from $200 to $220.
In another report released today, Morgan Stanley also reiterated a Buy rating on the stock with a $185.00 price target.